TLR9 and hepatocellular carcinoma: To determine the combined therapeutic effect of blocking TLR9 pathway and sorafenib, we established a DEN-induced HCC model in wild-type (Tlr9+/+) and Tlr9 knockout (Tlr9-/-) mice and treated the mice with or without sorafenib (Fig. 8A).